Common and uncommon histologic subtypes of renal cell carcinoma: imaging spectrum with pathologic correlation

Expression of CD9 and CD82 in clear cell renal cell carcinoma and its clinical significance

CD9 and CD82, members of the tetraspanin family, act as metastasis suppressors in many human malignant tumors, but the role of these molecules is not well known in clear cell renal cell carcinoma (CCRCC). This study was designed to evaluate the immunohistochemical expression of CD9 and CD82 in 644 cases of CCRCC and to determine the clinicopathologic and prognostic significance of their expression. The percentage of positive tumor cells was evaluated, and the expression was classified into 2 categories: low expression (less than 10% positive cells) or high expression (more than 10% positive cells) for CD9 expression and negative (no positive cells) or positive for CD82 expression. CD9 high expression was found in 303 (47.0%) patients, and CD82 positivity was found in 98 (15.2%) patients. High expression of CD9 was statistically associated with older patients (p=0.003). The cases showing positive immunoreactivity for CD82 exhibited a high stage (p<0.001) and high nuclear grade (p<0.001). The overall, cancer-specific and progression-free survival rates were significantly higher in patients with a CD82-negative profile compared to patients with a CD82-positive profile (p<0.001). Although the biological function of CD82 in CCRCC remains unclear, the CCRCC patients with CD82 positive expression show poor prognosis.

Chromophobe renal cell carcinoma: multiphase MDCT enhancement patterns and morphologic features

OBJECTIVE

The purpose of this investigation is to retrospectively describe morphologic features, enhancement characteristics, and clinical outcomes in a series of pathologically proven chromophobe renal cell carcinomas (RCCs).

MATERIALS AND METHODS

Thirty-five patients who were imaged at a single institution between 2005 and 2012 with pathologically proven chromophobe RCC were identified, all of whom underwent preoperative renal protocol CT (unenhanced, arterial, venous, and delayed images). The morphologic characteristics of each tumor (e.g., necrosis, tumor composition, and calcification), as well as attenuation values (in Hounsfield units) of the tumor, aorta, inferior vena cava, and kidney were evaluated by a board-certified radiologist. In addition, information regarding patient demographics and survival was obtained by a separate radiologist from the electronic medical record.

RESULTS

Sixty percent of the patients were men, with a mean age of 60.2 years. Forty-six percent of cases were incidentally identified, without patient symptoms. None of the patients had evidence of distant metastatic disease, either on initial staging CT or over the course of follow-up (mean, 2.0 years). Mean maximal tumor diameter was 5.24 cm. Forty-six percent of tumors were homogeneous, 85% of lesions were either completely solid or mostly solid, 14% showed calcifications, and 34% showed a central scar or necrosis. Mean maximum attenuation values were 87.9 HU (arterial phase), 83.9 HU (venous phase), and 60.6 HU (delayed phase), with an average delayed washout of 31%. Tumor-to-cortex ratios for the three enhanced phases were 0.59, 0.48, and 0.50, respectively.

CONCLUSION

Chromophobe RCCs were found to have a wider variability of CT features than previously reported, although they do have a greater propensity for homogeneity and the presence of a central scar or necrosis. Their enhancement characteristics fall in between those of clear cell and papillary RCC, although there is considerable overlap.

Utility of MRI features in differentiation of central renal cell carcinoma and renal pelvic urothelial carcinoma

OBJECTIVE

The purpose of this article is to evaluate the utility of various morphologic and quantitative MRI features in differentiating central renal cell carcinoma (RCC) from renal pelvic urothelial carcinoma.

MATERIALS AND METHODS

Sixty patients (39 men and 21 women; mean [± SD] age, 65 ± 14 years; 48 with central RCC and 12 with renal pelvic urothelial carcinoma) who underwent MRI, including diffusion-weighted imaging (b values, 0, 400, and 800 s/mm(2)) and dynamic contrast-enhanced imaging, before histopathologic confirmation were included. Tumor T2 signal intensity and apparent diffusion coefficients (ADCs) were measured and normalized to muscle and CSF (hereafter referred to as normalized T2 signal and normalized ADC, respectively) and then were compared using receiver operating characteristic analysis. Also, two blinded radiologists independently assessed all tumors for various qualitative features, which were compared with the Fisher exact test and unpaired Student t test.

RESULTS

Urothelial carcinoma exhibited significantly lower normalized ADC than did RCC (p = 0.008), but no significant difference was seen in ADC or normalized T2 signal intensity (p = 0.247-0.773). Normalized ADC had the highest area under the curve (0.757); normalized ADC below an optimal threshold of 0.451 was associated with sensitivity of 83% and specificity of 71% for diagnosing urothelial carcinoma. Features that were significantly more prevalent in urothelial carcinoma included global impression of urothelial carcinoma, location centered within the collecting system, collecting system defect, extension to the ureteropelvic junction, preserved renal shape, absence of cystic or necrotic areas, absence of hemorrhage, homogeneous enhancement, and hypovascularity (all p < 0.033). Increased T1 signal intensity suggestive of hemorrhage was significantly more prevalent in RCC (p = 0.02). Interreader agreement for the subjective features ranged from 61.7% to 98.3%.

CONCLUSION

In addition to various qualitative MRI parameters, normalized ADC has utility in differentiating central RCC from renal pelvic urothelial carcinoma. Such differentiation may assist decisions regarding possible biopsy and treatment planning.

Large cystic renal cell carcinoma leading to diagnostic dilemma: a case report

Large cystic renal tumours can be confused with hepatic lesions even on crosssectional imaging. Careful clinical, sonographic and imaging analysis is needed for establishing correct diagnosis. We report a case of papillary cystic renal carcinoma in a 60 year old man, which was confused with amoebic liver abcess and was initially drained. Subsequent recurrence of symptoms prompted us to re-evaluate the case and repeat sonography confirmed the extrahepatic origin of mass based on simple observation that the liver and mass were moving separately on inspiration. Later guided aspiration from solid component of the mass confirmed the diagnosis as renal cell carcinoma. He was successfully treated with radical nephrectomy with uneventful post-operative recovery.

Pretreatment differentiation of renal cell carcinoma subtypes by CT: the influence of different tumor enhancement measurement approaches

PURPOSE

We conducted a retrospective study to evaluate the influence of different tumor enhancement measurement approaches on the ability of computed tomography (CT) to differentiate between solid forms of clear cell renal cell carcinoma (RCC), other RCC histologic subtypes and oncocytomas. Different RCC subtypes have a diverse range of malignant potential; consequently, the information about RCC subtype obtained using minimally invasive imaging method before the treatment could allow the more accurate therapy planning. Differentiation of ccRCCs from oncocytomas is important because oncocytomas are usually benign tumors which could be treated conservatively.

METHODS

CT images of 113 patients with 118 solid renal tumors were evaluated. The imaging protocol consisted pre-contrast and post-contrast images during the arterial and nephrographic phases. Renal tumor attenuation values were measured using region of interest covering as much of the solid enhancing tumor tissue as possible. Tumor attenuation values and tumor enhancement ratios were correlated with histologic subtype. One hundred of tumors were diagnosed as clear cell RCC, nine as non-clear cell RCC and nine as oncocytoma.

RESULTS

Tumor attenuation values of >74 HU on the arterial phase scans significantly correlated with clear cell RCC (Az 0.73). The tumor-to-aorta enhancement ratios calculated on tumor attenuation values measured on the arterial phase scans had a cutoff value of >0.29, which significantly correlated with clear cell RCC (Az 0.79). All ROC curves for differentiating the clear cell RCC from oncocytomas have area under the curve too small (0.5 or less) to have chose cutoff value with sensitivity and specificity that could be applied in clinical work.

CONCLUSION

Enhancement measurements of renal carcinomas on CT images in the arterial phase can be used as an auxiliary method in the pretreatment differentiation of solid forms of the most frequent RCC subtypes in patients not suitable for core biopsy but who are suitable for minimally invasive treatment methods and/or targeted therapy.

Comparison of segmental enhancement inversion on biphasic MDCT between small renal oncocytomas and chromophobe renal cell carcinomas

OBJECTIVE

The purpose of this article is to assess the usefulness of segmental enhancement inversion on biphasic MDCT in differentiating small (<4 cm) renal oncocytomas from chromophobe renal cell carcinomas (CRCCs).

MATERIALS AND METHODS

Eighty-two patients (40 men and 42 women) with a mean (±SD) age of 54±12 years (range, 21-75 years) with 27 renal oncocytomas and 55 CRCCs diagnosed by surgery who underwent contrast-enhanced biphasic CT between January 2000 and December 2011 were included. CT scans were interpreted by two radiologists who were blinded to the pathologic findings. The tumors were evaluated for size and segmental enhancement inversion. After independent evaluation, a consensus was reached by measuring the attenuation. Pathologic analysis determined the presence of fibrous septa, cystic change, hemorrhage, and necrosis. The Fisher exact test was used to evaluate the relationship between segmental enhancement inversion, tumor type, and specific pathologic changes. Interobserver concordance was evaluated with kappa statistics.

RESULTS

There were no significant differences in size between renal oncocytomas and CRCCs (p=0.458). Segmental enhancement inversion was present in 23, 20, and 21 (25.6%) of the 82 tumors according to reader 1, reader 2, and the consensus, respectively. The agreement was almost perfect (κ=0.843; p<0.001). Segmental enhancement inversion was more common in renal oncocytomas (63% [17/27]) than in CRCCs (7.3% [4/55]; p<0.001). There were no significant relationships between the four pathologic changes and tumor type or segmental enhancement inversion (p=0.351 and p=0.126, respectively).

CONCLUSION

Our study findings suggest that segmental enhancement inversion on biphasic MDCT may be useful in differentiating small renal oncocytomas from CRCCs.

MDCT-based scoring system for differentiating angiomyolipoma with minimal fat from renal cell carcinoma

BACKGROUND

Subtype-related various computed tomography (CT) features of renal cell carcinoma (RCC) are a confusing factor in differentiating angiomyolipoma with minimal fat (AMLmf) from RCC. To overcome RCC heterogeneity, a scoring system, which integrates multiple discrimitive parameters can be helpful for differentiating AMLmf from RCC.

PURPOSE

To develop a MDCT-based scoring system for differentiating AMLmf from RCC.

MATERIAL AND METHODS

In 407 patients with pathologically confirmed 48 AMLmfs and 359 RCCs (247 clear cell RCCs, 67 papillary RCCs, and 45 chromophobe RCCs), MDCT features (ratio of long-to-short diameter, enhancement characteristics, tumor attenuation on unenhanced scan, tumor margin, calcification), age, and sex were compared between AMLmf and RCCs. Based on logistic regression, a scoring system for diagnosing AMLmf over RCC was built, and its diagnostic accuracy was evaluated.

RESULTS

Scores suggesting AMLmf, i.e. the logit function as used in logistic regression analysis, were calculated as follows: Score = e(6.16.A-0.003.B+1.20.C+0.97.D+2.13.E-0.05.F)/1+e(6.16.A-0.003.B+1.20.C+0.97.D+2.13.E-0.05.F), where A = ratio of long-to-short diameter, B = enhancement amount in early excretory phase, C = homogeneous enhancement, D = tumor attenuation on unenhanced scan, E = sex, and F = age. Area under receiver-operating characteristics curve of scoring system was 0.919. With a score of 0.204 or higher, the scoring system yielded greatest accuracy (90%, 368/407) for diagnosing AMLmf over RCC, which was greater than that of any single MDCT or clinical parameter (53-85%) (P < 0.05). With a score of 0.317 or higher, sensitivity and specificity were 68% (32/48) and 95% (340/359).

CONCLUSION

MDCT-based scoring system can improve diagnostic performance of MDCT in differentiating AMLmf from RCC and help patients with AMLmf to avoid unnecessary surgery with high specificity.

[Imaging renal cell carcinoma]

Renal cell carcinoma is the eighth most common malignancy in adults and the most common malignancy in the kidney. It is thus a very common disease for radiologists. This review aims to provide a general overview of the imaging techniques used to diagnose, characterize, and help plan the treatment of renal cell carcinoma as well as to review basic aspects related to staging, imaging-guided percutaneous treatment, and follow-up in the most common clinical scenarios.

Renal carcinomas associated with Xp11.2 translocations/TFE3 gene fusions: findings on MRI and computed tomography imaging

PURPOSE

To retrospectively analyze MRI and computed tomographic (CT) findings from renal carcinomas associated with Xp11.2 translocations/TFE3 gene fusions (Xp11-RCC).

MATERIALS AND METHODS

Institutional review board permission was obtained to review patient medical records, and the requirement for informed consent was waved . The clinical and MRI/CT features of five cases with Xp11-RCC that were confirmed by pathology were analyzed retrospectively. The image characteristics included the lesion location and size, contribution of cystic and solid components, intratumoral necrosis or hemorrhage, invasion of perinephric tissue and renal sinus, lymphadenopathy, major venous or arterial vascular invasion, pattern of the tumor growth, intratumor calcification and lipids, homogeneity of SI on T2-weighted images, attenuation and SI of the mass with respect to the normal renal cortex on precontrast and contrasted CT/MRI images, tumor SIs, tumor attenuations and tumor-to-cortex indices, homogeneity of enhancement on the contrasted images.

RESULTS

The mean age was 32 years (range, 15-47 years). Most patients (4/5) were women. All tumors showed a cortical location. The average tumor size was 9 cm (range, 4-18 cm). Four tumors comprised a predominantly solid lesion with focal necrosis, and one tumor comprised a solid lesion with significant necrosis. All tumors showed intertumor hemorrhage, infiltrative growth and invasion of the perirenal adipose/renal sinus. Four cases showed retroperitoneal lymphadenopathy, of which one case showed simultaneous mediastinal and supraclavicular lymphadenopathy. All tumors from four cases showed mild hyperintensity on T1-weighted MRI images, and three tumors showed hypointensity on T2-weighted MRI images relative to the renal cortex except for 1 tumor that showed significant hemorrhage and a relative hyperintensity. For 3 cases who were imaged with CT, two tumors imaged using nonenhanced CT images showed mild hyperdensity relative to the renal cortex. Calcification was noted in all three tumors. All tumors showed mild, persistent enhancement.

CONCLUSION

Typical Xp11-RCC manifests as an advanced, solid renal mass with mild persistent enhancement, a prevalence of intertumor hemorrhage/calcification, and a cortical epicenter location. The predilection for children and young adults is a useful clinical feature when confirming a diagnosis of Xp11-RCC.

Radiologic-pathologic correlation of renal cell carcinoma associated with Xp11.2 translocation

BACKGROUND

The prognosis of translocation RCCs in adult patients is relatively poor compared to that of other subtypes of RCCs. Although there have been several reports regarding radiologic findings of translocation RCC, studies with histologic correlation could help to understand the imaging features.

PURPOSE

To explore the correlation between radiologic and pathologic findings in Xp11.2 translocation renal cell carcinoma (RCC) and provide clues for translocation RCC diagnosis.

MATERIAL AND METHODS

CT scans of six patients (one man and five women; age range, 8-71 years; mean age, 34 years) with histologically-proven Xp11.2 translocation RCCs were retrospectively evaluated in consensus by two radiologists. Tumor size, presence of necrosis, hemorrhage, fat or calcification, enhancement patterns of the tumor, presence of lymphadenopathy, and distant metastases were evaluated.

RESULTS

The average size of the tumors was 6 cm (range, 2.7-12 cm). All six tumors appeared as well-defined masses with areas of low attenuation representing hemorrhage or necrosis. Four tumors contained high attenuating solid portions, compared to the surrounding renal cortex seen on unenhanced images, where representing dense cellular component on microscopic examination. Peripheral rim enhancement pattern that correlated with histologic finding of a fibrous capsule was seen in five cases. In two patients who underwent kidney MR, the masses showed low signal intensity on T2-weighted images. One patient had lymphadenopathy. No distant metastasis was noted in any patient.

CONCLUSION

Translocation RCC appeared as a well-defined mass that contain high attenuating solid portions on unenhanced images and low attenuating necrotic or hemorrhagic foci; the tumor also showed gradual peripheral rim enhancement due to a fibrous capsule surrounding the tumor.

Targeted therapies and the treatment of non-clear cell renal cell carcinoma

BACKGROUND

Targeted therapies have shown profound effects on the outcome of patients with advanced renal cell carcinoma (RCC). However, the optimal treatment for RCC of non-clear cell histology (nccRCC)-typically excluded from trials of targeted agents-remains uncertain.

MATERIALS AND METHODS

By carrying out extensive searches of PubMed and ASCO databases, we identified and summarised research into the biological characteristics, clinical behaviour and treatment of different histological subtypes of nccRCC, focusing on targeted therapy.

RESULTS

The available data suggest that treatments currently approved for RCC are active in ncc subtypes, although the overall clinical benefit may be less than for clear cell RCC. Temsirolimus has proven benefit over interferon-alfa (IFN-α) in patients with nccRCC, based on phase III data, while everolimus, sunitinib and sorafenib have all demonstrated some degree of activity in nccRCC in expanded-access trials. No clear picture has emerged of whether individual histological subtypes are particularly responsive to any individual treatment.

CONCLUSIONS

Further molecular studies into the pathogenesis of RCC histological subtypes will help direct the development of novel, appropriate targeted agents. Clinical trials specifically designed to evaluate the role of targeted agents in nccRCC are ongoing, and data from trials with sunitinib and everolimus will be reported soon.

Autosomal dominant polycystic kidney disease: prevalence of renal neoplasias in surgical kidney specimens

BACKGROUND

The role of autosomal dominant polycystic kidney disease (ADPKD) as a risk factor for renal cell carcinoma (RCC) is still under discussion. Data on prevalence of RCC in ADPKD are limited, especially on a large population scale. The aim of this study was to analyze the prevalence of RCC in ADPKD kidneys and characterize the clinical features of this coincidence.

METHODS

Based on our histopathological registry for ADPKD and the Else Kröner-Fresenius Registry, we retrospectively reviewed malignant and benign renal lesions in patients with ADPKD who had undergone renal surgery from 1988 to 2011.

RESULTS

240 ADPKD patients underwent 301 renal surgeries. Mean age at surgery was 54 years. Overall, 16 malignant and 11 benign lesions were analyzed in 301 kidneys (5.3%; 3.7%), meaning that 12/240 (5%; 1:20) patients presented with malignant renal lesions. 66.7% (8/12) of these patients had undergone dialysis prior to surgery. We found 10/16 (63%) papillary RCC, 5/16 (31%) clear cell RCC, and 1/16 (6%) papillary noninvasive urothelial cancer. Regarding all renal lesions, 6/17 (35.3%) patients had more than one histological finding in their kidneys. In 2 cases, metachronous metastases were removed. Mean follow-up was 66.7 months.

CONCLUSION

Kidney-related prevalence of RCC in ADPKD kidneys was surprisingly high. Whether or not this is due to chronic dialysis or due to the underlying disease is still speculative. Like other cystic renal diseases with an increased risk for RCC, the attending physician should be aware of the malignant potential of ADPKD, especially with concomitant dialysis.

Real-time elastography for distinguishing angiomyolipoma from renal cell carcinoma: preliminary observations

OBJECTIVE

The objective of this study was to determine the diagnostic performance of sonoelastography for differentiating angiomyolipomas from renal cell carcinomas.

SUBJECTS AND METHODS

Twenty-eight angiomyolipomas and 19 renal cell carcinomas were prospectively examined with real-time elastography. Lesions were classified according to four elastographic patterns on the basis of the distribution of the blue area (representing no strain and hardest tissue component). The elasticity patterns and the strain ratios of the angiomyolipomas and renal cell carcinomas were evaluated independently by two observers. Diagnostic performance and interobserver agreement were analyzed.

RESULTS

All angiomyolipomas were classified as having a high-strain elastographic pattern (blue areas in < 50% of lesion, considered type 1 or type 2) by both radiologists, whereas 18 of 19 renal cell carcinomas were classified as having a low-strain elastographic pattern (blue areas in ≥ 50% of lesion, considered type 3 or 4) by both radiologists. The respective mean strain ratios measured by two radiologists were 0.15 ± 0.06 and 0.18 ± 0.09 for the angiomyolipomas and 0.64 ± 0.15 and 0.63 ± 0.19 for the renal cell carcinomas. There were significant differences between the elasticity patterns and strain ratios for angiomyolipomas and renal cell carcinomas (p < 0.001). Interobserver agreement was excellent for elasticity patterns and strain ratios, with a weighted kappa coefficient of 0.96 and an intraclass correlation coefficient score of 0.95.

CONCLUSION

Our results show that real-time elastography may be useful in differentiating angiomyolipomas from renal cell carcinomas, by use of both elasticity patterns and strain ratios.

Renal cell carcinoma in a horseshoe kidney: radiology and pathology correlation

Renal cell carcinoma (RCC) is encountered in about 3% of all adult neoplasms. Presence of any kidney malformation can change the plan for surgical treatment of RCC with organ preserving surgery. We report a case of clear cell RCC in a horseshoe kidney. Computed tomography scan revealed a horseshoe kidney anomaly with a large mass in the left side. The diagnosis of RCC was confirmed by pathology and histology findings.

Estrogen inhibits renal cell carcinoma cell progression through estrogen receptor-β activation

Renal cell carcinoma (RCC) originates in the lining of the proximal convoluted tubule and accounts for approximately 3% of adult malignancies. The RCC incidence rate increases annually and is twofold higher in males than in females. Female hormones such as estrogen may play important roles during RCC carcinogenesis and result in significantly different incidence rates between males and females. In this study, we found that estrogen receptor β (ERβ) was more highly expressed in RCC cell lines (A498, RCC-1, 786-O, ACHN, and Caki-1) than in breast cancer cell lines (MCF-7 and HBL-100); however, no androgen receptor (AR) or estrogen receptor α (ERα) could be detected by western blot. In addition, proliferation of RCC cell lines was significantly decreased after estrogen (17-β-estradiol, E2) treatment. Since ERβ had been documented to be a potential tumor suppressor gene, we hypothesized that estrogen activates ERβ tumor suppressive function, which leads to different RCC incidence rates between males and females. We found that estrogen treatment inhibited cell proliferation, migration, invasion, and increased apoptosis of 786-O (high endogenous ERβ), and ERβ siRNA-induced silencing attenuated the estrogen-induced effects. Otherwise, ectopic ERβ expression in A498 (low endogenous ERβ) increased estrogen sensitivity and thus inhibited cell proliferation, migration, invasion, and increased apoptosis. Analysis of the molecular mechanisms revealed that estrogen-activated ERβ not only remarkably reduced growth hormone downstream signaling activation of the AKT, ERK, and JAK signaling pathways but also increased apoptotic cascade activation. In conclusion, this study found that estrogen-activated ERβ acts as a tumor suppressor. It may explain the different RCC incidence rates between males and females. Furthermore, it implies that ERβ may be a useful prognostic marker for RCC progression and a novel developmental direction for RCC treatment improvement.

Small solid renal masses: characterization by diffusion-weighted MRI at 3 T

AIM

To describe the appearance of small solid renal lesions (≤3 cm) on diffusion-weighted magnetic resonance imaging (MRI) and to determine whether ADC measurements may help to differentiate benign from malignant small solid renal masses.

METHODS AND MATERIALS

Thirty-five patients with 47 small renal masses (23 malignant, 24 benign) who underwent 3 T MRI of the kidney using diffusion-weighted sequences (b values of 0 and 1000 s/mm(2)) were retrospectively evaluated. Qualitative and quantitative analysis of diffusion-weighted images was performed.

RESULTS

Most lesions were hyperintense to kidney on high b-value diffusion-weighted images and hypointense on apparent diffusion coefficient (ADC) map. The mean ADC of the lesions was significantly lower than that of kidney (1.22 ± 0.3 versus 1.85 ± 0.12 mm(2)/s; p < 0.005). The mean ADC was significantly different between renal cell carcinomas (1.2 ± 0.01 mm(2)/s), metastases (1.25 ± 0.04 mm(2)/s), angiomyolipoma (1.07 ± 0.3 mm(2)/s) and oncocytomas (1.56 ± 0.08 mm(2)/s; p < 0.05). The mean ADC of clear cell renal cell carcinomas was significantly different from that of non-clear cell renal cell carcinomas (1.38 ± 0.34 versus 0.83 ± 0.34 mm(2)/s; p < 0.005). No significant difference was found between mean ADC of fat containing and minimal fat angiomyolipomas (1.06 ± 0.48 versus 1.11 ± 0.33 mm(2)/s).

CONCLUSION

Small solid renal masses are hyperintense on high b value and have different ADC values.

Preoperatively evaluating the correlation between pathological grades and blood oxygenation level-dependent MRI in clear cell renal cell carcinomas

RATIONALE AND OBJECTIVES

To assess whether r(2)* values can be used to determine the nuclear grade of clear cell renal cell carcinomas (CRCC).

MATERIALS AND METHODS

A total of 26 patients with pathologically proven CRCCs underwent blood oxygen level-dependent magnetic resonance imaging. r(2)* values were determined for the solid components of CRCC lesions. Histological nuclear grade was determined for each lesion. All patients were divided into low- and high-grade groups. r(2)* values were compared between different grades and between low- and high- grade groups. Receiver operating characteristic curve was drawn to establish the cutoff point for r(2)* values. The correlation between r(2)* values and pathological groups was assessed.

RESULTS

Low-grade group (grades I + II) contained 17 cases and high-grade group (grades III + IV) contained nine cases. The intraclass correlation coefficient for r(2)* values was 0.89. Significant difference was seen between different grades (P < .005). r(2)* values of the high-grade group were higher than the low-grade group (P < .005). A sensitivity of 78% and a specificity of 100% were achieved with a cutoff of 31.87 seconds(-1). r(2)* values directly correlated with pathological groups (P < .005).

CONCLUSION

r(2)* values of CRCCs could be employed as a noninvasive biomarker to help classify the nuclear grade of CRCC.

Pelvic nephroureterectomy for renal cell carcinoma in an ectopic kidney

We present a case of an ectopic renal tumor in a 61-year-old morbidly obese man with a pelvic kidney found after presenting with hematuria and irritative voiding symptoms. The mass, along with the ectopic kidney and ureter, was radically resected through an open operation that involved removing both them and the renal vessels from the underlying iliac vessels. Pathological analysis demonstrated an 8.3 cm papillary renal cell carcinoma (RCC) with oncocytic features, Fuhrman nuclear grade 3, with angiolymphatic invasion and negative margins. The patient has been recurrence-free for over four years since tumor resection.

Rare (<1%) histological subtypes of renal cell carcinoma: an update

Recent advances in genetics and pathology have allowed description of several new histological subtypes of renal cell carcinoma (RCC) as well as better characterization of other rare subtypes. We herein present a comprehensive review of taxonomy, epidemiology, pathology, imaging findings, and natural history of a wide spectrum of rare subtypes of RCCs that individually constitute <1% of all the RCCs.

Sarcomatoid renal cell carcinoma: a case report and literature review

Renal cell carcinoma (RCC) is the most common malignancy of the kidney and consists of multiple subtypes. The sarcomatoid variety, while previously considered a distinct histologic subtype, is now categorized as a form of dedifferentiated carcinoma. When present, it is associated with a significant decrease in patient survival due to its rapid growth and intrusive behavior. Preoperative knowledge of this diagnosis may be beneficial to clinicians in order to modify treatment options and follow-up protocols. This report describes a case of sarcomatoid renal cell carcinoma in which the patient initially presented with flank pain. We then discuss the clinical features of sarcomatoid renal cell carcinoma and its imaging appearance on computed tomography (CT), and succinctly review the subtypes of renal cell carcinoma and their imaging characteristics.

Common and uncommon adult unilateral renal masses other than renal cell carcinoma

Many different masses can involve the kidney other than the commonly encountered renal cell carcinoma (RCC). The purpose of this article is to review the characteristic clinical and imaging findings of common and uncommon masses that predominantly present unilaterally in the adult patient, other than RCC. Awareness of such lesions and knowing the clinical scenario is important for appropriate diagnosis and management, especially in a multidisciplinary care setting.

Diffusion-weighted MRI in renal cell carcinoma: a surrogate marker for predicting nuclear grade and histological subtype

BACKGROUND

Though previous investigators have attempted to evaluate its utility in characterization of focal renal lesions, diffusion-weighted MR imaging (DW MRI) in renal diseases is still an evolving field and its role in predicting the aggressiveness of renal cell carcinoma (RCC) is yet to be established.

PURPOSE

To assess whether apparent diffusion coefficient (ADC) values can be used to determine the nuclear grade and histological subtype of RCCs and to identify the tumor attributes contributing to variation in ADC values.

MATERIAL AND METHODS

The institutional ethics committee waived the requirement of informed consent for this retrospective study. The study cohort consisted of 33 patients who underwent MRI (with diffusion-weighted imaging at b values of 0 and 500 s/mm(2)) and were found to have 36 pathologically-proven RCCs. ADC values were determined for solid portions of RCC, cystic/hemorrhagic areas, and normal renal parenchyma. Histological subtype, nuclear grade, and cell count were determined for each lesion. ADC values were compared between different grades and subtypes and correlation with cell count was investigated. Receiver operating characteristic curves were drawn to establish cut-off ADC values.

RESULTS

There were 23 low grade (grades I and II) and 13 high grade tumors (grades III and IV). There were 32 clear-cell and four non-clear-cell RCCs. A decreasing trend of ADC values was seen with increasing grade and mean ADC of high grade RCC was significantly lower than low grade (1.3145 vs 1.6982 × 10(-3) mm(2)/s) (P = 0.005). Mean ADC for clear-cell RCC was significantly higher than non-clear-cell RCC (1.6245 vs. 1.0412 × 10(-3) mm(2)/s) (P = 0.005). ADC values higher than 1.7960 × 10(-3) mm(2)/s were seen only with low grade and values greater than 1.4904 × 10(-3) mm(2)/s were seen only with clear-cell RCC.

CONCLUSION

ADC values provide a non-invasive means to predict the nuclear grade and histological subtype of RCC. Cellularity and morphology are other tumor attributes contributing to the variation in ADC values of RCCs.

Multimodal imaging and detection strategy with 124 I-labeled chimeric monoclonal antibody cG250 for accurate localization and confirmation of extent of disease during laparoscopic and open surgical resection of clear cell renal cell carcinoma

Renal cell carcinoma (RCC) accounts for approximately 85% to 90% of all primary kidney malignancies, with clear cell RCC (ccRCC) constituting approximately 70% to 85% of all RCCs. This study describes an innovative multimodal imaging and detection strategy that uses ¹²⁴I-labeled chimeric monoclonal antibody G250 (¹²⁴I-cG250) for accurate preoperative and intraoperative localization and confirmation of extent of disease for both laparoscopic and open surgical resection of ccRCC. Two cases presented herein highlight how this technology can potentially guide complete surgical resection and confirm complete removal of all diseased tissues. This innovative ¹²⁴I-cG250 (ie, ¹²⁴I-girentuximab) multimodal imaging and detection approach, which would be clinically very useful to urologic surgeons, urologic medical oncologists, nuclear medicine physicians, radiologists, and pathologists who are involved in the care of ccRCC patients, holds great potential for improving the diagnostic accuracy, operative planning and approach, verification of disease resection, and monitoring for evidence of disease recurrence in ccRCC patients.

The expanding role of imaging in the management of renal cell carcinoma

The management of renal cell carcinoma (RCC) is evolving owing to the increasing detection of small renal masses, greater understanding of the metabolic pathways involved, new targeted medical treatments for metastatic RCC, and evolving surgical and minimally invasive image-guided treatment techniques. Consequently, the role of imaging and radiology has expanded, with new challenges encompassing all aspects of management, including diagnosis, predicting cell type, staging, preoperative vascular mapping, image-guided treatment and biopsy, detection of recurrence and the use of imaging as a biomarker to assess response to treatment. This article is a comprehensive review of RCC, outlining the etiology of the disease, RCC histological subtypes and their imaging characteristics, imaging modality techniques for evaluation of RCC, treatment strategies and the management of small renal masses.

Papillary renal cell carcinoma with extensive paraaortic nodal metastasis mimicking malignant lymphoma

A 52-year-old woman with abdominal distension underwent computed tomography (CT) that demonstrated extensive paraaortic lymphadenopathy and a right renal mass. Compared to the renal cortex, the lesions exhibited low signal intensity on T(1)- and T(2)-weighted images and high intensity on diffusion-weighted magnetic resonance (MR) images. We suspected malignant lymphoma and performed excisional biopsy, which revealed metastatic papillary renal cell carcinoma. Retrospectively, significantly reduced signal on in-phase chemical shift MR images compared to out-of-phase images suggested the presence of intratumoral hemosiderin, a characteristic finding of this entity.

TroVax® vaccine therapy for renal cell carcinoma

Renal cell carcinoma (RCC) is the most common primary malignancy affecting the kidney. In the past decade, several well-designed clinical trials have shifted the treatment paradigm for RCC to favor targeted therapies as first-line agents. Recognition of the immunogenic nature of RCC has also resulted in the development of immunotherapy approaches with high-dose IL-2 treatment being the best established and associated with durable disease control. The lack of defined antigens in RCC has hindered more specific vaccine development. TroVax® is a novel vaccine based on a modified vaccinia virus Ankara vector engineered to express the 5T4 tumor-associated antigen, found on over 95% of clear cell and papillary RCC tumors. The safety and efficacy of TroVax has been evaluated in several Phase I/II clinical trials and in a multicenter Phase III trial. This article will discuss the clinical background of RCC, the rationale for TroVax development, results of several TroVax clinical trials and future directions for optimizing TroVax therapy in patients with RCC and other cancers.

Imaging in renal cell carcinoma

Imaging plays a central role in the detection, diagnosis, staging, and follow-up of renal cell carcinoma (RCC). Most renal masses are incidentally detected with modern, high-resolution imaging techniques and a variety of management options exist for the renal masses encountered today. This article discusses the role of multiple imaging modalities in the diagnosis of RCC and the imaging features of specific pathologic subtypes and staging techniques. Future directions in RCC imaging are presented, including dynamic contrast-enhanced and unenhanced techniques, as well as the development of novel tracers for positron emission tomography.

Rhabdomyosarcoma-associated renal cell carcinoma: a link with constitutional Tp53 mutation

The 2004 World Health Organization classification includes the new entity "neuroblastoma-associated renal cell carcinoma." The pathogenetic link between these entities is unknown as yet. The patient reported herein developed renal cell carcinoma after anaplastic embryonal rhabdomyosarcoma, a previously unknown association. The 2nd malignancy developed very soon after the 1st one, prompting concern for inherent cancer predisposition rather than a therapy-induced 2nd malignancy. A variety of features raised suspicion for Tp53 mutation, and indeed a pathogenic germline Tp53 mutation was identified in this child, despite a negative family history for Li-Fraumeni syndrome. Consideration of underlying predisposition is advocated in the context of rapid evolution of 2nd childhood malignancy.

Novelties of treatment in advanced renal-cell cancer

Therapeutic options in advanced renal-cell cancer have expanded through better understanding of molecular patho­logy and development of novel targeted therapeutics. Vascular endothelial growth factor, the key ligand of angioge­nesis, has a major role in the progression of vascularized kidney tumors and this is the target molecule of modern medications. The three types of the mechanism of action of current therapies are: monoclonal antibodies blocking directly vascular endothelial growth factor ligand (bevacizumab), tyrosine-kinase inhibitors blocking vascular endothelial growth factor receptors (sorafenib, sunitinib, pazopanib) and inhibitors of the intracellular mTOR-kinase (temsirolimus, everolimus). Based on randomized studies, sunitinib, pazopanib or interferon-α-bevacizumab combination should be the first-line therapy in patients with good/moderate prognosis, while temsirolimus is recommended in those with poor prognosis. Following an ineffective cytokine therapy sorafenib or pazopanib are the se­cond-line treatment. In case of tyrosine-kinase inhibitor inefficacy, current evidence favors everolimus. Patient outcome can further be improved by the involvement of more modern and effective target products. Orv. Hetil., 2011, 152, 655–662.

Renal granular cell tumour (Abrikossoff tumour): case report and review of the literature

A 52-year-old female was referred to our institute for an incidental renal mass. A homogenously enhancing mass was detected on multidetector CT (MDCT) imaging. Histologically, the tumour was consistent with granular cell tumour (GCT). GCT is a benign tumour that often involves the skin and subcutaneous tissue. Rarely has it been reported to involve the genitourinary system. Here we present the first reported case of GCT with renal involvement along with its MDCT imaging features. The authors also present a review of the literature along with a review of typical MDCT imaging features of enhancing renal masses with emphasis given to renal cell carcinoma and its varying subtypes.

Angiogenesis of renal cell carcinoma: perfusion CT findings

OBJECTIVE

To observe the perfusion CT findings of renal cell carcinoma (RCC) and prospectively correlate perfusion CT parameters with tumor MVD and VEGF expression.

METHODS

Dynamic contrast-enhanced multislice spiral CT was performed prospectively in 73 cases with histologically proven RCC (65 clear cell, 3 papillary, and 5 chromophobe). Blood flow (BF), blood volume (BV), mean transit time (MTT), and permeability surface-area product (PS) of RCC and normal renal cortex were measured, respectively. The tumor MVD count and VEGF expression level were determined by immunohistochemistry with specific monoclonal antibodies.

RESULTS

There was significant difference between BF, BV, MTT, and PS of normal renal cortex (454.32 ± 110.90 mL/min/100 g, 23.53 ± 5.71 mL/100 g, 3.62 ± 1.38 s, 63.95 ± 18.85 mL/min/100 g) and RCC (261.96 ± 175.86 mL/min/100 g, 17.17 ± 8.34 mL/100 g, 7.08 ± 3.42 s, 25.07 ± 13.20 mL/min/100 g) (P < 0.01). BF and BV among RCC histologic subtypes were significantly different (P < 0.05), MTT and PS were not (P > 0.05). MVD (42.29 ± 21.00) of RCC is positively correlated with BF, BV, and PS (P < 0.01), not with MTT (P > 0.05). No relationship was found between the expression levels of VEGF and any perfusion CT parameter.

CONCLUSIONS

Perfusion CT is a feasible technique to assess tissue perfusion in patients with RCC. BV, BF, and PS correlate positively with MVD and may reflect angiogenesis of RCC.

Usefulness of diffusion-weighted imaging in the evaluation of renal masses

OBJECTIVE

The objective of our study was to assess the value of diffusion-weighted imaging in differentiating among the various subgroups of renal masses.

MATERIALS AND METHODS

This retrospective study measured the apparent diffusion coefficients (ADCs) of renal masses. Malignant lesions were confirmed with surgical pathology results. Benign cystic lesions were stable without treatment for a minimum follow-up of 24 months.

RESULTS

There were 20 and 22 patients, respectively, with benign lesions (three abscess, 31 cysts) and malignant lesions (17 clear cell, five papillary, one chromophobe, and two transitional cell cancers). The malignant lesions were larger than the benign lesions (mean diameter, 4.2 vs 2.6 cm, respectively; p = 0.01, Student's t test). The ADC values of the benign lesions were significantly higher than those of the malignant lesions (mean, 2.72 vs 1.88 x 10(-3) mm(2)/s; p < 0.0001). The ADCs of the 31 benign cysts were significantly higher than those of the seven cystic renal cancers (2.77 vs 2.02 x 10(-3) mm(2)/s; p < 0.001). There was no significant difference between the ADCs of clear cell cancers and non-clear cell cancers (1.85 vs 1.97 x 10(-3) mm(2)/s; p = 0.18), but an ADC of less than 1.79 x 10(-3) mm(2)/s was seen only with clear cell cancer. The ADCs of high-grade clear cell cancers (Fuhrman grades III and IV) tended to be lower than those of low-grade clear cell cancers (1.77 vs 1.95 x 10(-3) mm(2)/s; p = 0.12). Among the clear cell cancers, an ADC value of greater than 2.12 x 10(-3) mm(2)/s was seen only with low-grade histology. For differentiating benign from malignant lesions, receiver operating characteristic (ROC) analysis showed an area under the ROC curve of 0.989 (95% CI, 0.919-0.996; p < 0.0001).

CONCLUSION

ADC measurements may aid in differentiating among the various subgroups of renal masses, particularly benign cystic lesions from cystic renal cell cancers.

Chromophobe renal cell cancer--review of the literature and potential methods of treating metastatic disease

Chromophobe renal cell carcinoma (ChRCC) is a subtype of renal cell carcinoma (RCC). ChRCC is diagnosed mainly in 6th decade of life. An incidence of ChRCC is similar in both men and woman. Eighty six percent of ChRCCs cases are diagnosed in stage 1 or 2. Prognosis of ChRCC is better than in other types of RCC. Five- and 10-year disease free survival (DFS) for ChRCC was 83.9% and 77.9%, respectively. Expression of immunohistological markers: cytokeratins (CK), vimentin, epithelial membrane antigen (EMA), CD10 could be potentially helpful in diagnosis of different subtypes of RCC. From all conventional RCC, CD 117 was detected (overexpression) in membrane of cells ChRCC.Overexpression of CD117 on cellular membranes of ChRCC could be a potential target for kinase inhibitors like: imatinib, dasatinib, nilotinib. The potential targets for other kinase inhibitors (sunitinib and sorafenib) in ChRCC seem to be VEGFR and PDGFR. On the basis for formulating research hypotheses which should be verified by prospective studies.

Magnetic resonance imaging of renal masses

The increasing frequency of incidentally detected renal masses supports the need for accurate imaging characterization to avoid unnecessary surgery/interventional procedures. Furthermore, the need for accurate presurgical diagnosis of specific histologic subtypes of renal malignancies is increasingly important as advances in understanding of tumor biology direct targeted courses of therapy. Magnetic resonance imaging is uniquely suited for the evaluation of renal masses because of its ability to provide excellent soft-tissue contrast and demonstration of enhancement, as well as its multiplanar capabilities. Although the spectrum of masses that may occur in the kidneys is broad, specific imaging features may assist in their accurate diagnosis. Examples of the imaging appearance of common and uncommon renal masses are provided along with a protocol for comprehensive magnetic resonance examination of the kidneys.

Sternal metastasis as an initial presentation of renal cell carcinoma: a case report

Renal cell carcinoma accounts for 85% of all solid renal tumors in adults. Nearly one quarter of patients has distant metastasis at presentation while another 50% develop metastasis during follow-up. A small percentage of these are solitary metastasis. We report here a case of solitary bone sternal metastasis as an initial presentation of clear-cell renal cell carcinoma in a 56-year-old woman. The prognosis for patients with metastasized renal cell carcinoma is poor; treatment of metastasis is usually palliative and designed to provide comfort and pain relief. Palliative nephrectomy may be considered for control of symptoms. Radical nephrectomy associated with metastatic bone tumor resection is being tested to improve functional status and survival, especially when metastasis involves supporting bones.

[Imaging characterization of renal masses. Image atlas]

The diagnostic study, analysis and characterization of renal masses and their behavior is one of the key elements for elaborating a surgical or therapeutic strategy, determining the prognosis, and for the follow-up of treatment efficacy in patients with benign or malignant disease. At present, computed tomography (CT) and magnetic resonance imaging (MRI) are the two most reliable, effective and efficient instruments in this context--offering sensitivity and specificity values in excess of 87%, with a diagnostic relaibility of over 90% in application to renal masses of a cystic or complex nature, with nonspecific or specific inflammatory characteristics, or of a primary or secondary neoplastic nature. The aim of this study is to present the principal CT and MRI parameters in relation to renal pathology of this kind, correlating them to the clinical, physiopathological and histopathological data with a view to affording architectural, density, signal intensity and biological behavior parametric information of help in understanding the changes occurring in the renal and retroperitoneal regions secondary to such pathologies.